Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to $2.1 million.

  • Vanda Pharmaceuticals' Share-based Compensation fell 2957.65% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year decrease of 2172.56%. This contributed to the annual value of $12.4 million for FY2024, which is 1145.3% down from last year.
  • According to the latest figures from Q3 2025, Vanda Pharmaceuticals' Share-based Compensation is $2.1 million, which was down 2957.65% from $2.1 million recorded in Q2 2025.
  • Vanda Pharmaceuticals' 5-year Share-based Compensation high stood at $4.8 million for Q1 2022, and its period low was $2.1 million during Q2 2025.
  • For the 5-year period, Vanda Pharmaceuticals' Share-based Compensation averaged around $3.4 million, with its median value being $3.6 million (2024).
  • Per our database at Business Quant, Vanda Pharmaceuticals' Share-based Compensation surged by 2602.87% in 2021 and then tumbled by 2957.65% in 2025.
  • Vanda Pharmaceuticals' Share-based Compensation (Quarter) stood at $3.8 million in 2021, then increased by 0.24% to $3.8 million in 2022, then decreased by 13.48% to $3.3 million in 2023, then fell by 12.53% to $2.9 million in 2024, then decreased by 26.23% to $2.1 million in 2025.
  • Its Share-based Compensation stands at $2.1 million for Q3 2025, versus $2.1 million for Q2 2025 and $3.0 million for Q1 2025.